gms | German Medical Science

Deutscher Rheumatologiekongress 2023

51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)
37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)
33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

30.08. - 02.09.2023, Leipzig

Artikel

Artikel empfehlen

Development of clinically relevant biomarkers in patients with ANCA-associated vasculitides (AAV) in a longitudinal cohort of the University Medical Center Mainz – preliminary results

Meeting Abstract

Suche in Medline nach

  • Tamara Möckel - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz
  • Konstantinos Triantafyllias - Rheumatology Center Rhineland Palatinate, Bad Kreuznach
  • Andreas Schwarting - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz; Rheumatology Center Rhineland Palatinate, Bad Kreuznach
  • Silke Stellwagen - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz
  • Anna Trautwein - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz
  • Sebastian Boegel - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz
  • Tim Gaidies - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz
  • Birgit Ackermann - Rheumatology Center Rhineland Palatinate, Bad Kreuznach
  • Matthias Dreher - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz
  • Julie Rakebrand - University Medical Center of the Johannes Gutenberg University Mainz, Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Mainz

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Leipzig, 30.08.-02.09.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocVK.38

doi: 10.3205/23dgrh229, urn:nbn:de:0183-23dgrh2294

Veröffentlicht: 30. August 2023

© 2023 Möckel et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Introduction: Granulomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis) is assigned to the group of ANCA (anti-neutrophil cytoplasmatic antibody)-associated vasculitides (AVV) and characterized by systemic vasculitis with necrotizing granulomatous inflammation of respiratory tract and kidneys. Although myeloperoxidase (MPO) and proteinase 3 (PR3) are well known targets of ANCAs, there are still no suitable prognostic or therapy-related biomarkers available. Consequently, distinction between different forms of AVV or individualized therapy approaches according to disease severity and organ manifestation are limited.

Methods: In this study we aim to identify predictive, prognostic and therapy-related biomarkers in patients with ANCA-associated vasculitides (AVV) using high-throughput sequencing technologies. For this purpose, transcriptome of 20 therapy-naive GPA patients was analyzed in order to display relevant gene signatures and deduce conceivable biomarker candidates. Finally, bioinformatical data will be correlated with clinical parameters like disease activity, course of disease and serological parameters.

Results: Transcriptome analyses revealed no relevant interferon (IFN) or interleukin (IL) signatures so far, but a similar TNF (tumor necrosis factor) pattern with upregulated TNFRSF1A (TNF Receptor Superfamily Member 1A) across all samples. C5AR1 of the complement system was upregulated as well as other genes like CTSS, FCER1G, ITGB2, MSRB1, RHOG, S100A9, S100A12 and SERPINA1. Furthermore, S100A9 was also detected on protein level in serum samples of GPA patients. Thereby, levels of S100A9 showed differences during the course of disease. Follow-up samples showed a correlation of circulating S100A9 levels with disease activity, disease flares and treatment related effects.

Conclusion: Preliminary findings of this study revealed similar gene signatures of GPA patients. Furthermore, different TNF, complement system and other upregulated genes are conceivable biomarker candidates. In addition, our study showed the correlation of S100A9 expression with clinical data so far, but further investigations are needed to prove S100A9 and other candidates as reliable biomarkers for AVV.

Disclosure: Study is funded by Vifor.